Angiotensin Converting Enzyme 2 News and Research

RSS

Genome-based microbiome signature associated with the severity and prognosis of COVID-19 in hospitalized patients

Researchers evaluated the association between guild-level microbiome signature and the severity and prognosis of SARS-CoV-2 infections by a genome-level metagenomic analysis.

21 Sep 2022

New antiviral mechanism of action for an FDA-approved thiopurine known as 6-thioguanine

Researchers described a novel antiviral mechanism of action for an FDA (food and drug administration)-approved thiopurine known as 6-thioguanine (6-TG).

21 Sep 2022

Prophylactic administration of SARS-CoV-2 specific immunoglobulin Y generated in chicken eggs displays protective effects in infected mice

A new study characterized and tested the antibody activity of SARS-CoV-2-specific immunoglobulin Y (IgY) derived from the eggs laid by chickens immunized with recombinant SARS-CoV-2 receptor binding domain (RBD) protein.

21 Sep 2022

Study reveals increased immunity evasion by Omicron BA.2.75.2

In a recent study posted to the bioRxiv* preprint server, researchers from ETH Zurich, Imperial College London, and Karolinska Institutet identified increased resistance to antibody-mediated neutralization by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineage BA.2.75.2.

21 Sep 2022

No adverse affect on sperm quality 6 to 14 months post BNT162b2 COVID vaccine

A study published in the journal Gamete Biology demonstrates that the mRNA-based coronavirus disease 2019 (COVID-19) vaccine developed by Pfizer/BioNTech is not detrimental to sperm health over a long period post-vaccination.

20 Sep 2022

Endogenous exosomes act as decoys for SARS-CoV-2

A recent study published in the journal PLoS Biology discussed exosomes as potential decoys for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

20 Sep 2022

Molecular engineered low-cost highly effective RBD-based COVID vaccine

In a recent study posted to the bioRxiv* preprint server, an international team of researchers developed a second-generation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen (RBD-J6) by molecular engineering with two additional amino acid (aa) substitutions (S383D and L518D mutations) in a hydrophobic cryptic RBD core epitope to enhance stability and expression against SARS-CoV-2 variants of concern (VOCs).

19 Sep 2022

U of A research findings could give scientists the upper hand in tackling SARS-CoV-2

University of Alberta research shows how cell membranes play a much larger role than previously understood in allowing spike proteins on viruses to infect cells.

16 Sep 2022

SARS-CoV-2 N escape mutations do not affect rapid antigen testing

A new study maps the escape mutations found in various strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could cause them to escape neutralization by antibodies or detection by rapid antigen tests that rely on antibody binding for a positive result.

16 Sep 2022

Development of improved monoclonal antibodies against SARS-CoV-2

In a new study, researchers explored strategies for the development of effective monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2022

Research shows a complex relationship between vaping and SARS-CoV-2 infection

In a recent study posted to the bioRxiv* pre-print server, researchers at the University of California, Riverside investigated the effects of electronic cigarette (EC) use as a risk factor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

14 Sep 2022

Defensosomes versus COVID-19

In a recent study published in the journal PLoS Biology, researchers investigated the role of angiotensin-converting enzyme 2 (ACE2)-containing defensive exosomes, or 'defensosomes' against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

14 Sep 2022

Customized bivalent mRNA COVID boosters protect against BA.5 Omicron variant

In a recent study posted to the bioRxiv* pre-print server, researchers from Washington University School of Medicine, Moderna, Inc, and the U.S. National Institutes of Health tested two bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines based on the messenger ribonucleic acid (mRNA) platform.

14 Sep 2022

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

A new study suggested that an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine induced mucosal immune responses in mice.

14 Sep 2022

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.

14 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

In a recent study posted to the bioRxiv* server, researchers in the United States demonstrated the efficacy of a novel biopolymer, N-dihydrogalactochitosan (GC), as an adjuvant for next-generation mucosal coronavirus disease 2019 (COVID-19) vaccine.

12 Sep 2022

Review of COVID-19 in children before and after SARS-CoV-2 Delta and Omicron variant emergence

Researchers provided a summary of SARS-CoV-2 infections among children pre- and post-SARS-CoV-2 Delta and Omicron variants of concern (VOCs) emergence.

12 Sep 2022

What is the impact of COVID-19 vaccination on erectile function?

A recent study reported that COVID-19 vaccination does not elevate the risk of erectile dysfunction.

12 Sep 2022

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).

12 Sep 2022

Angiotensin Converting Enzyme 2 News and Research

Genome-based microbiome signature associated with the severity and prognosis of COVID-19 in hospitalized patients

New antiviral mechanism of action for an FDA-approved thiopurine known as 6-thioguanine

Prophylactic administration of SARS-CoV-2 specific immunoglobulin Y generated in chicken eggs displays protective effects in infected mice

Study reveals increased immunity evasion by Omicron BA.2.75.2

No adverse affect on sperm quality 6 to 14 months post BNT162b2 COVID vaccine

Endogenous exosomes act as decoys for SARS-CoV-2

Molecular engineered low-cost highly effective RBD-based COVID vaccine

U of A research findings could give scientists the upper hand in tackling SARS-CoV-2

SARS-CoV-2 N escape mutations do not affect rapid antigen testing

Development of improved monoclonal antibodies against SARS-CoV-2

Research shows a complex relationship between vaping and SARS-CoV-2 infection

Defensosomes versus COVID-19

Customized bivalent mRNA COVID boosters protect against BA.5 Omicron variant

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

Review of COVID-19 in children before and after SARS-CoV-2 Delta and Omicron variant emergence

What is the impact of COVID-19 vaccination on erectile function?

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News